Asia Pacific Antidiabetics Market Size & Outlook, 2024-2030
Related Markets
Asia Pacific antidiabetics market highlights
- The Asia Pacific antidiabetics market generated a revenue of USD 12,153.4 million in 2024.
- The market is expected to grow at a CAGR of 11.3% from 2025 to 2030.
- In terms of segment, glp-1 receptor agonists was the largest revenue generating drug class in 2024.
- GLP-1 Receptor Agonists is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 12,153.4 million |
| Market revenue in 2030 | USD 23,096.1 million |
| Growth rate | 11.3% (CAGR from 2025 to 2030) |
| Largest segment | Glp-1 receptor agonists |
| Fastest growing segment | GLP-1 Receptor Agonists |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors |
| Key market players worldwide | AstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Co Ltd, Eli Lilly and Co, Boehringer Ingelheim, Bristol-Myers Squibb Co, Pfizer Inc, Johnson & Johnson, Merck & Co Inc, Novartis AG ADR |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 13.3% of the global antidiabetics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 23,096.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antidiabetics Market Scope
Antidiabetics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Asia Pacific antidiabetics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antidiabetics market will help companies and investors design strategic landscapes.
Glp-1 receptor agonists was the largest segment with a revenue share of 38.76% in 2024. Horizon Databook has segmented the Asia Pacific antidiabetics market based on insulin, glp-1 receptor agonists, dpp- 4 inhibitors, sglt2 inhibitors covering the revenue growth of each sub-segment from 2018 to 2030.
The Asia Pacific antidiabetics market is estimated to register the fastest growth during the forecast period. The surge in type 2 diabetes cases is fueled by changes in lifestyle, urbanization, and dietary habits.
The region’s large and aging population base makes it a critical market for diabetes therapeutics. Additionally, the rapid expansion of telemedicine and digital health platforms is improving access to diabetes care.
The integration of technology into diabetes management is expected to further accelerate market penetration in the region.
Reasons to subscribe to Asia Pacific antidiabetics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific antidiabetics market databook
-
Our clientele includes a mix of antidiabetics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific antidiabetics market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific antidiabetics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific antidiabetics market size, by country, 2018-2030 (US$M)
Asia Pacific Antidiabetics Market Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
